NCT05487599 - A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

October 2, 2030

Study Completion Date

October 2, 2030

Conditions

Gaucher DiseaseGaucher Disease, Type 1

Interventions

GENETIC

LY3884961

• LY3884961 is a replication-incompetent recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.

Trial Locations (8)

2145

RECRUITING

Westmead Hospital-Cnr Hawkesbury and Darcy Rds, Westmead

50006

RECRUITING

Hospital Quironsalud Zaragoza, Paseo Mariano Renovales Sn, Zaragoza

60611

RECRUITING

Ann and Robert H Lurie Children's Hospital of Chicago, Chicago

65239

RECRUITING

SphinCS Clinical Science for LSD, Höchheim

27710-3017

RECRUITING

Duke University Health System, Durham

22030-6066

RECRUITING

Lysosomal & Rare Disorders Research and Treatment Center, Fairfax

90035-903

RECRUITING

Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre

Unknown

RECRUITING

Royal Free Hospital NHS Trust, London